Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…

Donanemab Shows Promising Results in Slowing Cognitive Decline in Alzheimer’s Disease

Donanemab Shows Promising Results in Slowing Cognitive Decline in Alzheimer’s Disease

Introduction Eli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’s Association International Conference (AAIC). The study focused on evaluating the effectiveness of donanemab, a potential treatment for early symptomatic Alzheimer’s disease (AD). The results, also published in the Journal of the American Medical Association (JAMA), demonstrated that…

Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug

Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug

Roche Launches Legal Battle Against Biogen’s Imitative Biosimilar of Blockbuster Arthritis Drug July 14, 2023  – Roche (ROG.S) and its subsidiary powerhouses have taken a decisive step by initiating legal proceedings against biotech frontrunner Biogen (BIIB.O) in the federal court of Massachusetts. Their grievance centers around Biogen’s audacious attempt to replicate Roche’s highly successful drug…

Revolutionizing Antibody Design: Harnessing the Power of Generative AI

Revolutionizing Antibody Design: Harnessing the Power of Generative AI

Introduction The field of generative artificial intelligence has seen remarkable advancements in recent years, enabling machines to create images and generate text. However, its potential goes far beyond art and literature. Absci Corporation, a pioneering company in antibody therapeutics, is leveraging generative AI to revolutionize drug discovery. By harnessing the power of machine learning, Absci can…

Lexington’s Cyteir Therapeutics to Close Two Years After IPO

Lexington’s Cyteir Therapeutics to Close Two Years After IPO

A Lexington-based biotech firm, Cyteir Therapeutics Inc., has declared its plan to disband a mere two years following its public debut via an IPO. The company’s announcement on Friday included intends to cease the development of its solitary drug, a clinical-stage program designed to treat ovarian and other solid-tumor cancers. Cyteir aims to liquidate its…

Roche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Roche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…

FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, Leqembi

FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, Leqembi

Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…